Hypothesis

Aging endothelial cells undergo senescence and release extracellular vesicles (EVs) enriched in ultra‑large von Willebrand factor (vWF) multimers and Factor VIII (FVIII). These EV‑associated complexes bypass normal clearance pathways, augment circulating vWF/FVIII levels, and provide a surface that accelerates thrombin generation beyond what soluble plasma factors alone can achieve. The ABO blood group modulates this process because A‑antigen residues on vWF within EVs reduce recognition by hepatic Ashwell‑Morell receptors, slowing clearance especially in non‑O individuals.

Mechanistic Rationale

1. Endothelial senescence increases EV shedding – Senescent endothelial cells upregulate pathways such as p53/p21 and secrete EVs containing cargo reflective of their activation state, including vWF stored in Weibel‑Palade bodies and bound FVIII. Senescence‑associated secretory phenotype (SASP) cytokines further promote EV biogenesis.[https://pubmed.ncbi.nlm.nih.gov/41193118/]
2. EV‑bound vWF resists proteolytic cleavage – Within EVs, vWF is shielded from ADAMTS13, preserving ultra‑large multimers that have higher thrombotic activity. This protection explains the observed rise in vWF multimeric size with age.[https://pmc.ncbi.nlm.nih.gov/articles/PMC12577834/]
3. ABO glycosylation alters EV clearance – The A‑antigen on vWF masks galactose residues, decreasing binding to hepatic lectin receptors that normally remove desialylated glycoproteins. Consequently, EVs from non‑O donors persist longer in circulation, amplifying the age‑related increase seen in β coefficients.[https://pubmed.ncbi.nlm.nih.gov/26875505/]
4. EV surfaces potentiate thrombin generation – Phosphatidylserine and tissue factor displayed on senescent‑derived EVs provide a procoagulant platform that locally concentrates vWF/FVIII, enhancing endogenous thrombin potential (ETP) and peak thrombin measurements. This accounts for the strong correlation between plasma vWF/FVIII and ETP (r=0.702) and peak thrombin (r=0.533) beyond what soluble factors predict.[https://pubmed.ncbi.nlm.nih.gov/16676066/]

Testable Predictions

• EV isolation – Plasma EVs from individuals aged >60 y will contain significantly higher vWF antigen and activity per particle than those from <30 y donors, after adjusting for total EV count.
• ABO effect – Non‑O subjects will show a greater ratio of EV‑associated vWF to soluble plasma vWF compared with O subjects, reflecting slower clearance.
• Functional assay – Depleting EVs from aged plasma (via ultracentrifugation or immuno‑capture) will reduce ETP and peak thrombin by ≥20 % compared with whole plasma, whereas adding EVs from senescent endothelial cell cultures to young plasma will raise these parameters.
• In‑vitro senescence – Inducing endothelial senescence (e.g., with doxorubicin or irradiation) will increase EV release and EV‑bound vWF/FVIII; inhibiting SASP with JAK inhibitors will attenuate this effect.
• In‑vivo validation – Administering a pharmacological senolytic (e.g., dasatinib + quercetin) to aged mice will lower circulating EV‑vWF levels and normalize thrombin generation assays.

Implications

If confirmed, this hypothesis shifts the focus from purely soluble plasma alterations to a cellular‑derived vesicle mechanism that integrates endothelial aging, ABO genetics, and thrombotic risk. It also suggests that senolytic or EV‑targeting strategies could complement current anticoagulant approaches, offering a refined avenue for risk stratification and intervention in elderly populations.